ArtFile Clear

Executive summary

ArtFile Clear is a done-for-you reporting operations desk for independent and small multi-site US fertility clinics that must annually submit cycle-level Assisted Reproductive Technology (ART) data to CDC’s National ART Surveillance System (NASS) — and, for SART members, through SART CORS — under the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA). The buyer is not buying another EMR co-pilot. They are buying a Reporting-Year Completeness Pack: every in-scope cycle accounted for, outcome chase queue exhausted or documented, validation errors cleared, and a medical-director-ready verification binder released before the public non-reporter listing clock expires.

Evidence threshold clears: federal mandate with public non-reporter shaming (48 clinics / 9.6% in 2021); verified labor intensity (trade press: ~2 admin days per 20 patients for outcome chase; embryologists reportedly spending majority of day on compliance admin); existing budget in EMR exports, registry consultants, and emerging AI outcome tools (BabySentry, eIVF, EmbryoLogix, Cercle AI, FertilityPro); a hard-diff from the manifest’s IVF prior-authorization desk; a narrow remote MVP (Outcome Chase Completeness Pack for one reporting year); and a credible 50%+ gross-margin path as extraction and chase automation harden.

Absolute walls: never practices medicine; never submits to NASS/SART as the clinic; never invents birth/pregnancy outcomes; never alters success-rate denominators; never signs as medical director; never hourly billing; HIPAA BAA required before PHI intake.

Thesis

Fertility clinics already pay for EMR systems that can export registry files — yet the binding constraint is not “can the EMR spit a CSV?” It is the year-long, document-heavy chase for pregnancy and live-birth outcomes from OBs and patients who sit outside the clinic’s EMR, followed by field-level validation against NASS/SART rules and medical-director verification. That chase + validation + binder workflow is structured enough for AI extraction and orchestration, judgment-bounded enough to need a human registry specialist RELEASE, and reputation-sensitive enough (public success rates + non-reporter listing) that clinics will pay for a done-for-you outcome rather than operate another dashboard. Revenue scales with cycles-under-management and clinics-on-continuity, not with proportional embryology headcount.

Discovery rationale

This run cloned ainbis fresh (900 prior runs through PrivilegeTrue Clear) and steered away from saturated EHS/permit/compliance-engine clusters per Section 28. Keyword and semantic sweeps confirmed InterestTrue (security-deposit interest), veterinary DEA desks, NEMT compliance desk, IVF cycle prior-auth desk, and CPSC recall desks already claim adjacent lanes. Fresh research across fertility administration, CDC NASS, SART CORS, commercial-scale registration, Texas OSSF, and blood lookback surfaces found CDC NASS / SART outcome-reporting operations uniquely open: same vertical as the IVF auth desk but a different trigger (annual federal registry deadline), workflow (outcome chase + field validation + MD verification binder), and outcome sold (submission-ready Completeness Pack, not payer authorization). Buyer pain is publicly documented in fertility trade press and paid for today via EMR modules, weekend embryologist time, and registry consultants.

Candidate comparison

Five candidates scored 1–5 across required dimensions; six-gate averages shown.

CODE validation

Rubric scorecard (six gates)

Six-gate total: 27 / 30 · Average: 4.35

Target buyer

ICP: Independent US fertility / REI clinics and small groups (1–4 sites) performing roughly 150–750 ART cycles/year, SART member or NASS-direct reporter, without a full-time registry data manager. Beachhead: clinics that missed or nearly missed a prior deadline, recently changed EMR, or are PE-backed roll-ups standardizing reporting ops.

Economic buyer: Practice owner / Medical Director / COO. Champion: Lab director, senior embryologist, or clinic data coordinator who currently owns weekend outcome chase.

Jobs-to-be-Done

• When reporting year closes, help me account for every started cycle so CDC/SART does not list us as a non-reporter.
• When pregnancy outcomes live outside our EMR, chase and structure them without burning embryologist weekends.
• When validation errors return from the portal, clear them with a defensible evidence trail before the deadline.
• When the medical director must verify, give a signature-ready binder — not a spreadsheet archaeology project.

Painful problem

ART outcomes are knowable only ~9–10 months after cycle start. Clinics must then assemble patient demographics, diagnoses, procedure parameters, and pregnancy/birth results — often by manually emailing/texting/calling OBs and patients — then pass NASS/SART validation and obtain medical-director verification. Trade press reports ~2 full admin days per 20 patients, up to two-thirds of some embryologists’ time on non-revenue admin, and ~6% human transcription error rates that can move public success statistics. Missing the window means public non-reporter listing (48 clinics / 9.6% in 2021) with an empty clinic page and reputational damage in a patient-choice market.

The outcome we sell

Specialist-released Reporting-Year Completeness Pack for one clinic and one reporting year: cycle census, outcome-chase status ledger, exception queue with documented non-responses, field-validation clearance log, draft NASS/SART import artifacts (where EMR allows), and medical-director verification binder. Optional year-round Continuity Desk runs monthly chase so December is not a fire drill. Client remains the reporting entity; medical director remains the verifier/signer.

First one-feature MVP wedge

Evidence summary

• Verified FCSRCA mandates annual ART reporting to CDC; NASS is the CDC-approved system (~500 clinics).
• Verified 2021: 453 reporters / 48 non-reporters (9.6%); non-reporters publicly listed.
• Verified CDC: outcomes reportable only after births complete (~Sept/Oct of year Y+1); typical submission deadline Dec 15 of year Y+1.
• Verified Fertility Bridge / IRH: ~2 admin days / 20 patients; embryologist admin load; ~6% human error (Cercle-sponsored article — labeled as such).
• Verified Incumbent budget: BabySentry/eIVF/MedITEX registry exports; EmbryoLogix validation SaaS; FertilityPro consulting; Cercle AI outcome extraction.
• Inferred Independent 150–750-cycle clinics are the underserved segment vs. large PE platforms with internal data teams.

Claim table

Source-claim matrix

*Trade article is paid featured content sponsored by Cercle AI; labor claims treated as directional Verified-from-trade, not government statistics.

Market and demand evidence

CDC estimates ~500 US ART clinics. IBISWorld sizes Fertility Clinics at $10.9B revenue / 576 businesses (2026). Cycle volume more than doubled over a decade (176k→414k, 2012–2021). Reporting is mandatory; the only statutory consequence for non-reporting is public listing — which still matters because patients and referring physicians use CDC/SART success-rate pages. Demand shows up as: (1) non-reporter pages every year; (2) EMR vendors advertising SART/NASS exports; (3) specialized validation SaaS and AI outcome tools; (4) trade press describing weekend chase as a staffing and reputation crisis.

Active buyer conversations

• Inside Reproductive Health / Fertility Bridge coverage of SART/CDC admin burden and embryologist time theft.
• NASS Help Desk channel (1-888-650-0822) for new clinics and submission questions — indicates ongoing operational friction.
• Vendor landing pages (EmbryoLogix, FertilityPro, Cercle) explicitly selling relief from validation-error loops and outcome chase.
• SART membership materials emphasizing annual verified submission and yearly validation sampling (≈8–10% of clinics).

Competitive landscape

Competitor and budget validation

Budget already exists as: EMR license (often five figures+/year), registry modules, embryologist overtime, temporary data-entry help in Q3–Q4, and specialty consultants. Redirecting a fraction of weekend clinical labor plus a seasonal contractor budget into a flat Completeness Pack is the economic story — not inventing a new spend category. Existing tools leave the operational chase and specialist RELEASE unfinished; that is the wedge.

Pricing evidence and proposed pricing

Primary model is per reporting-year Completeness Pack and per-clinic Continuity — never hourly.

Pricing is Unverified planning range anchored to seasonal contractor / consultant displacement, not published competitor rate cards.

Regulatory and compliance considerations

• FCSRCA (Pub. L. 102-493; 42 U.S.C. §263a-1 et seq.) requires annual ART data reporting.
• NASS is the CDC-approved reporting system; SART CORS commonly fulfills the federal obligation for members.
• Medical director verification/signature required for inclusion.
• CDC conducts annual validation sampling; discrepancy rates are published.
• ART data protected under PHSA §308(d) Assurance of Confidentiality; operators must use HIPAA BAAs, minimum necessary PHI, and secure transfer.
• Non-reporting consequence is public listing — reputational, not a civil money penalty schedule like many CMS programs.

Licensing boundary

AI-native advantage

AI changes unit economics by turning unstructured OB emails/PDFs/portal error dumps into structured cycle fields, running deterministic NASS rule checks at machine speed, and prioritizing chase queues by due date and missingness — so one specialist can RELEASE multiple clinics per week. The product is not “ChatGPT for IVF”; it is an internal production engine with SOPs, gold-standard packs, and audit trails that improve as models improve.

Internal AI engine architecture (10 layers)

1. Intake — BAA portal; encrypted cycle export; contact/consent flags.
2. Normalization — Map EMR schemas (eIVF/BabySentry/MedITEX/CSV) to canonical cycle objects.
3. Retrieval/knowledge — Versioned NASS/SART field dictionaries and prior-year clinic maps.
4. AI workbench — OCR/LLM extraction of outcomes from OB replies; missing-field proposals.
5. Deterministic rules — Required-field matrix; date logic; banking vs transfer cycle rules; duplicate detection.
6. Human chokepoint — Specialist RELEASE / HOLD; never auto-submit.
7. QA — Second-pass sample; invented-outcome red-team; PHI minimization check.
8. Delivery — Completeness Pack + MD binder PDF/portal.
9. Learning loop — Error taxonomy → prompt/SOP updates.
10. Model-portability — Swap LLM providers without changing SOPs or client artifacts.

AI-vs-human operations pipeline

Dynasty translation layer

• Buyer: Clinic COO/MD pays to avoid non-reporter listing and weekend embryologist burn.
• Service: DFY Completeness Pack + optional Continuity; customer receives released binder, not software login as the product.
• Workflow: Intake → extract → validate → chase → RELEASE → MD verify → client submit → renew.
• Tooling: Secure portal, spreadsheet/DB, LLM extraction, email sequences; custom software only after 20 pilots.
• Sales: “We deliver your medical-director-ready NASS pack before Dec 15 — you don’t live in the portal.”
• Delivery: Manual-heavy first 3 clients; automate extraction/chase templates next.
• Expansion: Multi-site packs, validation-visit binders, network playbooks.

Anti-duplication analysis

Manifest contains independent-fertility-clinic-ivf-cycle-auth-completeness-desk (payer prior auth) — different trigger, workflow, buyer job, and outcome. Also distinct from CPSC recall, pharmacy DSCSA, and generic healthcare credentialing desks. ArtFile’s sold outcome is federal registry Completeness Pack + outcome chase Continuity, not authorization letters or clinical decision support.

Anti-commoditization analysis

If general models make field mapping easier, clinics still need chase operations, exception documentation, PHI-safe processes, clinic-specific schema maps, and a specialist RELEASE before MD signature. SaaS exporters still leave the last mile undone. Defensibility = operations product (SOPs, gold packs, deadline clocks, audit trails), not model weights.

Service delivery workflow

1. Sales Gap Snapshot → BAA + pilot SOW.
2. Secure intake of cycle export and chase contacts.
3. AI normalize + deterministic completeness score.
4. Chase sequences for missing outcomes (clinic-approved scripts).
5. Validation clearance against NASS/SART rules.
6. Specialist RELEASE Completeness Pack.
7. MD verification meeting (client).
8. Client submits; ArtFile archives evidence.
9. Optional Continuity monthly chase.

Operations as product

Structured intake checklist; required evidence list (cycle IDs, outcome docs, lab cert status); automated completeness checks; exception queues (no-response, ambiguous outcome, schema mismatch); reviewer assignment; confidence scoring; audit trail; versioned field dictionaries; gold-standard packs; red-team invented-outcome checks; root-cause postmortems on every late or incomplete unit.

No-holes quality engine

• Hard block: no RELEASE if any cycle lacks either outcome or documented exception.
• Hard block: no invented DOB/birthweight/outcome codes.
• Sample QA ≥10% of cycles or 25 cycles, whichever greater.
• PHI egress scan before delivery.
• Deadline clock with red/yellow/green clinic dashboard for ops (internal).

What the human expert actually does

Minimum viable offer

First paid offer: Outcome Chase Completeness Pack for one reporting year, founding $4,500–$9,500, capped at 5 pilot clinics. Includes Gap Snapshot, chase for missing outcomes, validation clearance, and MD binder. Continuity sold only after Pack delivery succeeds.

Fulfillment process (first 3 customers)

1. Manual secure folder + spreadsheet tracker.
2. LLM-assisted extraction with human verification every field.
3. Clinic-approved email/SMS templates for chase.
4. Specialist builds binder in Google Docs/PDF.
5. Do not automate portal submission; do not skip MD review.
6. After 3: templatize schema maps per EMR.

Tools and systems

Day one: HIPAA BAA (e.g., signed MSA), encrypted file exchange, Notion/Airtable ops board, LLM API with zero-retention where available, email sequence tool under clinic’s domain or approved vendor, PDF binder generator. Later: light custom app for cycle census and exception queues. Prefer simple tools before platform build.

Human-in-the-loop quality control

Every pack requires specialist RELEASE. Any outcome extracted solely from unstructured text with confidence < threshold requires second human check. Invented-outcome red-team monthly. Client MD verification is a hard external chokepoint — ArtFile never bypasses it.

Nonlinear scaling and unit economics

COGS breakdown: model inference; secure hosting; specialist minutes; QA sample; support; sales follow-up; compliance documentation. No filing fees to CDC. CAC payback: aim ≤2 Completeness Packs or ≤6 Continuity months. Conversion assumptions (Unverified): Gap Snapshot→Pack 15–30%; Pack→Continuity 40–60%; annual retention 70%+ if Continuity starts before Q2.

Distribution proof table

Sales and outreach plan

Lead with diagnosis: “Show me last year’s chase spreadsheet and portal error dump — we’ll return a Gap Snapshot in 5 business days.” Convert to Completeness Pack with fixed scope bands by cycle count. Never lead with AI. Never hourly.

Founder-led content plan

Teach the exact pain: non-reporter pages, outcome chase math, validation error patterns, MD verification checklists, what EMR exports do and do not finish, and how CDC validation visits work. No generic “AI for fertility” thought leadership.

First 30 days of content

1. What FCSRCA actually requires (plain English).
2. How to read a CDC non-reporter listing.
3. Dec 15 countdown calendar template.
4. Outcome chase sequence that respects patient loss.
5. Top 10 NASS validation errors (pattern library).
6. EMR export ≠ Completeness Pack (tear-down).
7. What medical directors should refuse to sign.
8. How CDC validation sampling works.
9. Multi-site roll-up reporting traps.
10. PHI minimum-necessary checklist for vendors.
11. Diagnostic teardown A: anonymized chase ledger before/after.
12. Diagnostic teardown B: portal error dump decoded.
13. Diagnostic teardown C: missing banking-cycle fields.
14. Lead magnet 1: Reporting Gap Snapshot (25 cycles).
15. Lead magnet 2: Deadline + evidence checklist PDF.
16. Webinar: Live MD-binder review clinic.
17. Outbound template: personalized non-reporter-risk memo referencing clinic’s public CDC page status.

Lead magnet and waitlist plan

Lead magnet: Free Reporting Gap Snapshot — 25-cycle sample completeness score + deadline calendar + top missing-field classes. Waitlist CTA: “Reserve a founding Completeness Pack slot before Q3 lock.” Snapshot creates trust by showing holes without requiring full PHI dump initially (can use de-identified cycle IDs). Sales-ready when clinic shares BAA + full export and names an MD verifier.

Warm GTM plan

Convert Snapshot users; ask ASRM contacts for intros; offer scoped pilots to clinics that publicly struggled or recently switched EMR; partner with boutique fertility consultants who lack automation.

Targeted outbound plan

List independent clinics from CDC clinic directory; personalize around their public reporting status and cycle band; send a one-page Opportunity Memo (“your public page / deadline math / Gap Snapshot offer”), not a generic demo ask.

Answer-engine / search visibility plan

Publish canonical pages answering: “What is the CDC NASS deadline?”, “What happens if a fertility clinic does not report to CDC?”, “SART CORS vs NASS”, “How to prepare a medical director verification binder.” Structure with clear citations to CDC/OMB primary sources.

Pilot design and early-demand-trap mitigation

Pilot cap: 5 clinics. Incentive: founding Pack pricing. Learning goals: schema map time per EMR, chase response rates, specialist minutes, rework causes. Product feedback vs custom work: field-dictionary improvements = product; one-off clinical chart interpretation = out of scope / escalate to client. Do not scale by hiring chase farms without SOPs.

Early-access feedback flywheel

Every HOLD reason tagged → SOP/rule/prompt update weekly. Gold packs promoted from RELEASED units with zero rework. Client corrections become retrieval examples. Custom one-offs logged but not sold as platform features until seen in ≥3 clinics.

Build-before-scale checkpoints

• After 5 pilots: harden intake evidence requirements + QA checks.
• After 10: harden SOPs, exception queues, reviewer checklists, delivery templates.
• After 20: pause new logos until COGS, rework, escalation, and cycle time are measured; then automate.

7-day / 30-day / 90-day launch plans

7-day: BAA template, Gap Snapshot workflow, 10 outbound memos, 2 content posts, waitlist page.

30-day: 3 Snapshot deliveries, 1 paid Pack in flight, EMR schema map v1 (eIVF or BabySentry), content set from §30days underway.

90-day: 5 Packs completed or in MD verification, Continuity offer live for ≥2, measured COGS, decide whether to build light app.

Metrics and KPIs

• Cycle completeness % at RELEASE
• Documented-exception %
• Specialist hours / Pack
• Rework rate after MD review
• On-time delivery vs client lock date
• Snapshot→Pack conversion
• Pack→Continuity conversion
• Gross margin / Pack
• PHI incident count (target 0)

Risks and mitigations

Seasonality (Q3–Q4 spike) mitigated by Continuity. Sponsored-labor stats may overstate pain — validate in pilots. Small clinic TAM requires high ACV and Continuity. HIPAA breach is existential — BAA, minimum necessary, no training on client PHI. EMR vendors may bundle chase features — lean into DFY RELEASE differentiation.

Exhaustive risk register

What could kill this

If pilots show clinics will not share cycle exports under BAA; if Pack prices cannot clear COGS at ≤400 cycles; if a dominant EMR ships a true DFY chase service included in license; or if a preventable PHI incident occurs — shut down or pivot rather than scale.

Go/no-go reasoning

GO — Blueprint. Clears evidence threshold: clear buyer, painful specific problem, verified mandate and non-reporter consequence, verified labor/budget signals, competitor/budget validation, narrow MVP, remote fulfillment, licensing wall explicit, 50%+ margin path credible, distribution path believable, not a duplicate of the IVF auth desk or a customer-operated co-pilot.

Final recommendation

Launch ArtFile Clear with a 5-clinic founding cohort selling Outcome Chase Completeness Packs ahead of the next NASS deadline, convert successful Packs into Continuity Desks, and refuse any work that invents outcomes or bypasses medical-director verification. Measure COGS and rework before expanding past 20 clinics.

Source list

1. CDC — National ART Surveillance System
2. CDC — NASS Data Validation
3. CDC — 2021 ART Fertility Clinic and National Summary Report (PDF)
4. OMB ICR 0920-0556 — ART Program Reporting System
5. CDC — View ART Data (national summary)
6. Fertility Bridge / Inside Reproductive Health — Manual SART and CDC compliance
7. PMC — SART CORS IVF registry review
8. SART CORS Clinic Landing
9. EmbryoLogix
10. BabySentry
11. eIVF
12. FertilityPro consulting
13. IBISWorld — Fertility Clinics in the US
14. Harris Williams — Fertility Sector Brief Q4 2024
15. CRS — ART Regulation and Oversight
16. NASS reporting portal
17. OpenClaw — fertility clinic SART notes (secondary)